Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
Commentary|Articles|June 5, 2026
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
Author(s)Ashling Wahner
Fact checked by: Chris Ryan, Tracy Ann Politowicz
Breast cancer data from ASCO 2026 confirm the clinical benefits of several investigational treatment approaches across disease subtypes.
Advertisement
Advertisement
Throughout the
Related to this article
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.
Advertisement
Advertisement